中医药基于“肺-肠”轴调节肠道菌群治疗重症肺炎机制的研究进展

doi:10.20047/j.issn1673-7210.2023.06.07

Abstract
Figure/Table
References (32)
Related Citation (15)

Download: PDF (533 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Severe pneumonia (SP) is one of the common critical respiratory diseases. With the development of the “lung- intestinal” axis theory, the relationship between gut microbiota and lung diseases has become a research hotspot. In recent years, many studies have been carried out on the regulation of intestinal microbiota in the treatment of SP by traditional Chinese medicine, and the results show that intestinal microbiota will become a new target for the prevention and treatment of SP by traditional Chinese medicine. Based on the basic theory of traditional Chinese medicine, this paper takes intestinal microbiota as the target, and sorts out the correlation research of traditional Chinese medicine regulating intestinal microbiota in the treatment of SP through the “lung- intestinal” axis, in order to provide guiding significance for the clinical treatment of SP.

Key words： “Lung-intestinal”axis Intestinal flora Severe pneumonia Mechanism Traditional Chinese medicine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LUO Cheng1 YE Yuanhang1 ZHENG Lan2 KE Jia2

Cite this article:

LUO Cheng1 YE Yuanhang1 ZHENG Lan2 KE Jia2. Research progress of traditional Chinese medicine based on “lung-intestinal” axis regulating intestinal flora in the treatment of severe pneumonia[J]. 中国医药导报, 2023, 20(6): 33-36.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.06.07 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I6/33

[1] Garg M，Johri S，Sagar S，et al. Cardiolipin-mediated PPARgamma S112 phosphorylation impairs IL-10 production and inflammation resolution during bacterial pneumonia [J]. Cell Rep，2021，34（6）：108736.
[2] Garnacho-Montero J，Barrero-Garcia I，Gomez-Prieto MG，et al. Severe community-acquired pneumonia：current management and future therapeutic alternatives [J]. Expert Rev Anti Infect Ther，2018，16（9）：667-677.
[3] Alvarez J，Fernandez RJ，Guarner F，et al. Gut microbes and health [J]. Gastroenterol Hepatol，2021，44（7）：519-535.
[4] Chunxi L，Haiyue L，Yanxia L，et al. The Gut Microbiota and Respiratory Diseases：New Evidence [J]. J Immunol Res，2020，2020：2340670.
[5] Zhao Y，Liu Y，Li S，et al. Role of lung and gut microbiota on lung cancer pathogenesis [J]. J Cancer Res Clin Oncol，2021，147（8）：2177-2186.
[6] 李轶峰，刘超，尹皓原.重症肺炎患者外周血Treg/Th17及其相关细胞因子与肠道菌群的相关性[J].标记免疫分析与临床，2021，28（2）：318-321.
[7] Cruz CS，Ricci MF，Vieira AT. Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections [J]. Front Pharmacol，2021，12：724033.
[8] 邰贺，李顺民，陈剑平，等.基于“肺与大肠相表里”探讨调节“肠道微生物组”对糖尿病肺损伤的影响[J].世界科学技术-中医药现代化，2022，24（8）：2932-2937.
[9] Stanfield BA，Purves T，Palmer S，et al. IL-10 and class 1 histone deacetylases act synergistically and independently on the secretion of proinflammatory mediators in alveolar macrophages [J]. PLoS One，2021，16（1）：e245169.
[10] Li X，Wu D，Niu J，et al. Intestinal Flora：A Pivotal Role in Investigation of Traditional Chinese Medicine[J]. Am J Chin Med，2021，49（2）：237-268.
[11] Lin TL，Lu CC，Lai WF，et al. Role of gut microbiota in identification of novel TCM-derived active metabolites [J]. Protein Cell，2021，12（5）：394-410.
[12] 包晟川，闫曙光，陈婷，等.肺肠合治法治疗肺系疾病的研究进展[J].中国实验方剂学杂志，2022，28（8）：116- 122.
[13] Huo J，Wang T，Wei B，et al. Integrated network pharmacology and intestinal flora analysis to determine the protective effect of Xuanbai-Chengqi decoction on lung and gut injuries in influenza virus-infected mice [J]. J Ethnopharmacol，2022，298：115649.
[14] 耿欢，游丽娇，杨小芳，等.“肺与大肠相表里”理论在重症肺炎治疗中的应用探析[J].中国中医急症，2022，31（1）：84-86.
[15] Tang S，Liu W，Zhao Q，et al. Combination of polysaccharides from Astragalus membranaceus and Codonopsis pilosula ameliorated mice colitis and underlying mechanisms [J]. J Ethnopharmacol，2021，264：113280.
[16] 田雨，丁艳平，邵宝平，等.黄芪等药食同源类中药作为功能性食品与肠道菌群的相互作用[J].中国中药杂志，2020，45（11）：2486-2492.
[17] Zhu L，Ye C，Hu B，et al. Regulation of gut microbiota and intestinal metabolites by Poria cocos oligosaccharides improves glycolipid metabolism disturbance in high-fat diet-fed mice [J]. J Nutr Biochem，2022，107：109019.
[18] Zhang M，Wang Y，Wu Y，et al. In Vitro Transformation of Protopanaxadiol Saponins in Human Intestinal Flora and Its Effect on Intestinal Flora [J]. Evid Based Complement Alternat Med，2021，2021：1735803.
[19] 滕晋，王丹，向露，等.参苓白术颗粒预防老年抗生素相关性肠道菌群失调的RCT研究[J].成都中医药大学学报，2015，38（3）：52-54.
[20] 苏梦达，徐嘉辉.调肠方辅助治疗重症肺炎伴胃肠功能障碍31例临床观察[J].中国民族民间医药，2020，29（4）：106-110.
[21] 刘怀全，秦忠，朱星，等.基于肠道菌群理论探讨千金苇茎汤治疗呼吸系统疾病的潜在靶点[J].中华中医药学刊，2020，38（2）：41-43.
[22] 朱桂松，吴同启，傅元冬，等.芎黄合剂治疗重症肺炎合并胃肠功能障碍临床观察[J].中国中西医结合杂志，2017， 37（8）：909-912.
[23] 赵东凯，刘继民，刘通，等.中医外治法在COPD肺康复中的应用现状[J].吉林中医药，2020，40（11）：1537-1540.
[24] 滕金艳，周仲瑜，姚敏，等.艾灸在肺系疾病中的应用与研究进展[J].针灸临床杂志，2021，37（10）：88-92.
[25] 毕伟博，崔红生，陈秋仪，等.超声中药离子导入法在肺系疾病中的应用[J].中医杂志，2021，62（22）：1963-1966.
[26] 虞意华，金肖青，俞迈红，等.针刺治疗老年重症肺炎合并胃肠功能障碍的临床观察[J].中华中医药杂志，2016， 31（4）：1520-1522.
[27] 麦明杰，邓珂，谭泳梅，等.中药灌肠结合针刺疗法治疗ICU重症感染合并胃肠功能障碍的有效性研究[J].名医，2021（4）：73-74.
[28] 刘婷婷.穴位贴敷联合针刺治疗危重患者胃肠功能障碍的临床观察[J].中医临床研究，2018，10（14）：38-40.
[29] Youssef JG，Bitar MZ，Zahiruddin F，et al. Brief Report：Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With Ⅳ Vasoactive Intestinal Peptide [J]. Critical Care Explorations，2022，4（1）：e0607.
[30] Mukherjee T，Behl T，Sharma S，et al. Anticipated pharmacological role of Aviptadil on COVID-19 [J]. Environ Sci Pollut Res Int，2021，29（6）：8109-8125.
[31] 郝淑坤，何静，于子晨，等.柴芩麻膏汤内服结合保留灌肠对老年重症肺炎合并胃肠功能障碍的临床疗效及实验室指标的影响[J].中国中西医结合消化杂志，2022， 30（5）：309-313.
[32] 吴少丽.医用磁贴联合通腑泻肺方治疗重症肺炎合并胃肠功能障碍的临床疗效评价[J].中医临床研究，2020， 12（31）：88-90.